OCTA in Epivascular Glia After Dex Implant

Evaluation of Changes in Epivascular Glia Before and After Intravitreal Dexamethasone Implant : an OCT Pilot Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05600179

Enrollment

Registered

2022-10-31

Start date

2021-01-01

Completion date

2022-09-30

Last updated

2022-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Retinopathy

Brief summary

The aim of this prospective study was for the first time, to analyze specific morphologic features in diabetic eyes with macular oedema, such as changes of the foveal avascular zone and the presence of epivascular glia, and see how they would change after dexamethasone intravitreal implant

Interventions

DRUGDexamethasone intravitreal implant

Dexamethasone intravitreal implant

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* diabetic retinopathy complicated by macular edema

Exclusion criteria

* congenital eye disorders, * previous diagnosis of other ocular diseases * history of vitreous hemorrhage

Design outcomes

Primary

Measure	Time frame
Changes in epivascular glia after Dexamethasone implant in patients with diabetic retinopathy and inflammatory macular edema	up to 6 months

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026